Refreshing results…
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
UploadTwo-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial
Download from doi.orgMissing publications? Search for publications with a matching author name.